Abstract: Objective To observe the clinical management and safety of China Children Asthma Action Plan(CCAAP) in children with bronchial asthma. Methods A total of 64 children with bronchial asthma in the Pediatric Department of Baoding First Central Hospital from October 2017 to October 2018 were enrolled in this study,and were randomly divided into two groups by random number table method. The observation group(n=34) was managed by CCAAP,while the control group(n=30) received traditional management.The efficacy,pulmonary function,immune function and side effect of two groups were compared. Results Compared with the control group,the treatment effect of the observation group was better(97.06% vs.80.00%,χ²=4.761,P=0.029).The forced expiratory volume in 1 second(FEV1),FEV1/forced vital capacity(FEV1/FVC),FEV1/pred,25% of the maximal mid-expiratory flow(MEF25),MEF50,MEF75,CD3+,CD4+ and CD4+/CD8+ were significantly higher than those in control group,while the IgE and IL-4 levels decreased(P＜0.05).Moreover,the rates of acute attack(14.71% vs.50.00%) and complications(2.00% vs.10.00%) in the observation group were significantly lower(P＜0.05). Conclusion The CCAAP can improve the efficacy and safety of bronchial asthma in children and help improve pulmonary function and immune function.

Key words: China Children Asthma Action Plan, bronchial asthma, clinical management

摘要： 目的 观察实行中国儿童哮喘行动计划(CCAAP)对儿童支气管哮喘的临床管理效果和安全性。方法 选择2017年10月-2018年10月保定市第一中心医院儿科诊治的64例确诊为支气管哮喘的患儿,随机分为两组:治疗组(34例)采用CCAAP管理,对照组(30例)采用传统管理,对比两组治疗效果、急性哮喘发作次数、肺功能、免疫功能和并发症。结果 治疗组总控制效果优于对照组(97.06% vs.80.00%,χ²=4.761, P=0.029)。治疗组第1秒用力呼气容积(FEV1)、FEV1与用力肺活量(FVC)的比值(FEV1/FVC)、FEV1占预计值百分数(FEV1/pred)、用力呼气25%流速(MEF25)、MEF50、MEF75、CD3+、CD4+和CD4+/CD8+均较对照组显著增高(P＜0.05),免疫球蛋白E(IgE)和白细胞介素-4(IL-4)显著降低(P＜0.05),急性发作率(14.71% vs.50.00%,P＜0.05)和并发症发生较低(2.00% vs.10.00%,P＜0.05)。结论 CCAAP可提高儿童支气管哮喘治疗效果和安全性,并有助于改善患儿肺功能和免疫功能。

关键词: 中国儿童哮喘行动计划, 支气管哮喘, 临床管理